National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

anakinra
A recombinant human nonglycosylated interleukin-1 (IL-1) receptor antagonist with potential antineoplastic activity. Anakinra binds to the IL-1 receptor, thereby blocking the binding of the IL-1 to and activation of its receptor. Blockade of IL-1 activity may inhibit the cascade of downstream pro-angiogenic factors such as vascular endothelial cell growth factor, tumor necrosis factor-alpha, and IL-6, resulting in inhibition of tumor angiogenesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:IL-1ra
interleukin-1 receptor antagonist
US brand name:Kineret



Previous:Ampligen, Amplimexon, amrubicin hydrochloride, Amsa P-D, amsacrine
Next:anamorelin hydrochloride, anastrozole, anaxirone, Ancef, Ancestim

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov